• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.

作者信息

Wallenburg Eveline, Ter Heine Rob, Schouten Jeroen A, Raaijmakers Jelmer, Ten Oever Jaap, Kolwijck Eva, Burger David M, Pickkers Peter, Frenzel Tim, Brüggemann Roger J M

机构信息

Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, 864, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.

Department of Intensive Care, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Clin Pharmacokinet. 2022 Sep;61(9):1325-1329. doi: 10.1007/s40262-022-01165-8.

DOI:10.1007/s40262-022-01165-8
PMID:35947361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9439970/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/fe8e613d4655/40262_2022_1165_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/782abf694ac9/40262_2022_1165_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/6b6409fc64d7/40262_2022_1165_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/fe8e613d4655/40262_2022_1165_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/782abf694ac9/40262_2022_1165_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/6b6409fc64d7/40262_2022_1165_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a34/9439970/fe8e613d4655/40262_2022_1165_Fig5_HTML.jpg

相似文献

1
Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.对《危重症患者血浆和尿液中哌拉西林和他唑巴坦的整合药代动力学分析》的勘误
Clin Pharmacokinet. 2022 Sep;61(9):1325-1329. doi: 10.1007/s40262-022-01165-8.
2
Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.体外膜肺氧合患者中哌拉西林他唑巴坦的群体药代动力学和剂量优化及肾替代治疗的影响。
Microbiol Spectr. 2021 Dec 22;9(3):e0063321. doi: 10.1128/Spectrum.00633-21.
3
Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.哌拉西林他唑巴坦在接受连续性静脉-静脉血液透析滤过的危重症患者血浆和皮下组织间液中的药代动力学。
Int J Antimicrob Agents. 2014 Apr;43(4):343-8. doi: 10.1016/j.ijantimicag.2014.01.009. Epub 2014 Feb 10.
4
Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.在接受持续肾脏替代治疗的重症患者中，哌拉西林-他唑巴坦延长4小时输注的药代动力学。
Pharmacotherapy. 2015 Jun;35(6):600-7. doi: 10.1002/phar.1604.
5
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.在危重症患者中使用基于药代动力学/药效学的剂量计算器评估头孢吡肟、美罗培南和哌拉西林他唑巴坦的药效学目标达成情况。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.01008-18. Print 2018 Sep.
6
Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.接受万古霉素联合哌拉西林 - 他唑巴坦或头孢吡肟的重症患者急性肾损伤的比较发病率：一项回顾性队列研究
Pharmacotherapy. 2016 May;36(5):463-71. doi: 10.1002/phar.1738. Epub 2016 Apr 1.
7
Pulmonary penetration of piperacillin and tazobactam in critically ill patients.哌拉西林和他唑巴坦在重症患者中的肺部渗透情况。
Clin Pharmacol Ther. 2014 Oct;96(4):438-48. doi: 10.1038/clpt.2014.131. Epub 2014 Jun 13.
8
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?美罗培南和哌拉西林/他唑巴坦在重症患者中的处方：当采用延长输注时，肾脏清除率增加是否会影响药代动力学/药效学目标的达成？
Crit Care. 2013 May 3;17(3):R84. doi: 10.1186/cc12705.
9
Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin-Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study.评估接受万古霉素和/或哌拉西林他唑巴坦治疗的危重症患者的肾应激：多中心 Sapphire 研究的二次分析。
Drug Saf. 2019 Oct;42(10):1149-1155. doi: 10.1007/s40264-019-00846-x.
10
Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.危重症患者哌拉西林持续输注的群体药代动力学。
Int J Antimicrob Agents. 2018 Apr;51(4):594-600. doi: 10.1016/j.ijantimicag.2017.12.015. Epub 2017 Dec 22.

引用本文的文献

1
Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting.朝向哌拉西林的模型指导下精准给药：以贝叶斯预测为重点，对危重症成年患者的药代动力学模型进行多中心系统外部评估。
Intensive Care Med. 2023 Aug;49(8):966-976. doi: 10.1007/s00134-023-07154-0. Epub 2023 Jul 13.